Top Biobanking Companies

Biobanking Market size was valued at USD 76.9 Billion in 2024 and is poised to grow from USD 82.12 Billion in 2025 to USD 139.01 Billion by 2033, growing at a CAGR of 6.8% during the forecast period (2026–2033).

The competitive environment of the Biobanking market is dynamic and characterized by the presence of several key players engaging in strategic initiatives to solidify their market position. Established companies often focus on expanding their service offerings, investing in advanced technologies, and forming partnerships with research institutions and pharmaceutical companies. Additionally, mergers and acquisitions play a role in enhancing capabilities and extending geographic reach. The market's dynamism is further fueled by the entry of new players, particularly in emerging regions, contributing to increased competition. 'Thermo Fisher Scientific Inc. (United States)', 'Merck KGaA (Germany) ', 'QIAGEN N.V. (Netherlands) ', 'Hamilton Company (United States) ', 'Tecan Trading AG (Switzerland) ', 'Becton, Dickinson and Company (BD) (United States) ', 'Lonza Group AG (Switzerland) ', 'Charles River Laboratories International, Inc. (United States) ', 'BioLife Solutions, Inc. (United States) ', 'Brooks Automation, Inc. (United States) ', 'Greiner Bio-One International GmbH (Austria) ', 'STEMCELL Technologies Inc. (Canada) ', 'Chart Industries, Inc. (United States) ', 'BioIVT (United States) ', 'Firalis S.A. (France) ', 'Celltex Therapeutics Corporation (United States) ', 'Sigma-Aldrich Corporation (United States) ', 'Hope Biosciences (United States) ', '54Gene (Nigeria)'

A key driver of the biobanking market is the rapid growth in genomics research and personalized medicine. As the understanding of genetic markers and disease progression increases, the demand for biobanks storing high-quality biosamples for genomic analysis increases. These biosamples are essential for researchers to develop targeted therapies so is personalized medicine, making biobanking central to the future of healthcare. 

Integrating Artificial Intelligence (AI) and Big Data Analytics: One of the most important trends in the biobanking market is the integration of artificial intelligence (AI) and big data analytics. This technology helps biobanks optimize specimen tracking, improve data management, and improve the quality of specimen storage. AI-driven analytics enable researchers to identify patterns and insights from large biosample datasets, facilitating the discovery of the new biomarkers and accelerating drug development processes. 

North America plays an important role in the global biobanking market, driven by advanced healthcare infrastructure, strong research capabilities and an increasing emphasis on innovation in medical research and personalized medicine. North America is hub to many of the world's leading research institutes, universities, and biopharmaceutical companies. These organizations actively participate in biobanking initiatives to support cutting-edge research in genomics, oncology, and personalized medicine. Collaboration between academic institutions and industry stakeholders supports innovation and accelerates the discovery of new treatments, making this area a hub for biobanking activities.